Nobivac^® L4 Questions and Answers

• L. interrogans serogroup Canicola serovar Canicola to reduce infection and urinary excretion
• L. interrogans serogroup Icterohaemorrhagiae serovar Copenhageni to reduce infection and urinary excretion
• L. interrogans serogroup Australis serovar Bratislava to reduce infection
• L. kirschneri serogroup Grippotyphosa serovar Bananal/Liangguang to reduce infection and urinary excretion

Administer two vaccinations of 1 dose (1 ml) of vaccine with an interval of 4 weeks to dogs from 6 weeks of age onwards.

The first vaccination can be administered from 6 to 9* weeks of age and the second vaccination from 10 to 13 weeks of age.

*In cases of a high level of MDA, first vaccination is recommended at 9 weeks of age

Duration of immunity: 1 year.

Revaccination: Dogs should be re-vaccinated annually with one dose (1 ml) of vaccine

The onset of immunity following the 2^nd vaccination of the primary course is 3 weeks.

Safety and efficacy data are available which demonstrate that this vaccine can be mixed and administered with vaccines of the Nobivac series containing canine distemper virus, canine adenovirus type 2, canine parvovirus (strain 154) and/or canine parainfluenza virus components for subcutaneous administration. The product information of the relevant Nobivac vaccines should be consulted before administration of the mixed product. 

Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day but not mixed with vaccines of the Nobivac series containing Bordetella bronchiseptica and/or parainfluenza virus components for intranasal administration.

Safety data are available which demonstrate that this vaccine can be administered at the same time but not mixed with the inactivated vaccine of the Nobivac series against Bordetella bronchiseptica.

For simultaneous use, 1 dose of a Nobivac vaccine containing canine distemper virus, canine adenovirus type 2, canine parvovirus, and/or canine parainfluenza virus components should be reconstituted with 1 dose (1 ml) of Nobivac L4. The mixed vaccines should be at room temperature (15 °C – 25 °C) before they are administered by subcutaneous injection.
 

Nobivac L4 can be used during pregnancy.

We do not hold specific data regarding use during lactation and therefore cannot recommend this use during this period.

There are no breed specific contraindications for Nobivac L4.

Nobivac L4 requires storage in a refrigerator between 2 ^oC and 8 ^oC. Do not freeze. Protect from light.